Publicacións en colaboración con investigadores/as de Complexo Hospitalario Universitario de Pontevedra (48)

2024

  1. A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinoma

    Frontiers in Immunology, Vol. 15

  2. Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?

    British Journal of Cancer, Vol. 130, Núm. 5, pp. 777-787

  3. Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1674-1686

2023

  1. Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme

    European Journal of Cancer, Vol. 182, pp. 3-14

  2. Role of systemic inflammatory factors in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with peptide receptor radionuclide therapy (PRRT): From biology to theragnosis

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 42, Núm. 3, pp. 156-162

2022

  1. Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer

    Clinical and Translational Oncology, Vol. 24, Núm. 6, pp. 1209-1214

  2. Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group

    Cancer Treatment and Research Communications, Vol. 33

2021

  1. Dynamic perspective of the neutrophil-to-lymphocyte ratio in metastatic gastric cancer

    Journal of B.U.ON., Vol. 26, Núm. 5, pp. 2131-2140

  2. Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain

    BMC Cancer, Vol. 21, Núm. 1

  3. Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group

    Journal of Geriatric Oncology, Vol. 12, Núm. 3, pp. 410-415

  4. Evolution of c-reactive protein and procalcitonin serum levels after hepatic resection

    Revista de Cirugia, Vol. 73, Núm. 3, pp. 249-255

  5. Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data

    Scientific Reports, Vol. 11, Núm. 1

  6. Real-life use of ramucirumab in gastric cancer in Spain: The RAMIS study

    Future Oncology, Vol. 17, Núm. 14, pp. 1777-1791

  7. The role of intestinal microbiota in the colorectal carcinogenesis

    Foundations of Colorectal Cancer (Elsevier), pp. 495-512

2020

  1. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer

    European Urology, Vol. 78, Núm. 5, pp. 652-656

  2. Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram

    Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 351-359

  3. First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trial

    Clinical and Translational Oncology, Vol. 22, Núm. 4, pp. 495-502

  4. Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma

    Case Reports in Dermatology, Vol. 12, Núm. 1, pp. 37-41

2019

  1. Are reactive C protein and procalcitonin useful for early diagnosis of postoperative intraabdominal infection after pancreaticoduodenectomy for pancreatic cancer?

    Cirugia y Cirujanos (English Edition), Vol. 87, Núm. 6, pp. 662-666

  2. BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

    Journal of Patient-Reported Outcomes, Vol. 3, Núm. 1